3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ADMA Biologics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was 86.86%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ADMA Biologics's 3-Year ROIIC % or its related term are showing as below:
ADMA's 3-Year ROIIC % is ranked better than 80.27% of 1419
companies
in the Biotechnology industry
Industry Median: -16.71
vs ADMA: 86.86
ADMA Biologics 3-Year ROIIC % Historical Data
The historical data trend for ADMA Biologics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ADMA Biologics's 3-Year ROIIC %
For the Biotechnology subindustry, ADMA Biologics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics's 3-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's 3-Year ROIIC % falls into.
ADMA Biologics 3-Year ROIIC % Calculation
ADMA Biologics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 21.632 (Dec. 2023) - -64.915 (Dec. 2020) )
/
( 232.162 (Dec. 2023) - 132.52 (Dec. 2020) )
=
86.547
/
99.642
=
86.86%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ADMA Biologics 3-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 